How Should Investors Approach Exact Sciences in 2020?

A leader in the cancer diagnostics space with a focus on early detection, Exact Sciences (NASDAQ: EXAS) had a successful 2019, with 78% year-over-year revenue growth of its key cancer screening product, Cologuard. Cologuard is a non-invasive first-line test that detects colon cancer and people can take at home. If the test is positive, it indicates a colonoscopy is needed and if it's negative, the person can avoid a colonoscopy.

The number of Cologuard screenings performed in the year saw a huge increase -- a total of more than 1.68 million, more tests than were done in 2017 and 2018 combined. Revenue has also increased steadily in recent years, showing that the company is well-positioned for long-term success. So if management continues to execute effectively, the company should be set up to achieve its growth targets.

Image Source: Getty Images

Source Fool.com